Associated Papers
Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes.
Kim JJ et al.
Cancer Research and Treatment, 2024
37475138 (PubMed )
Supplement: crt-2023-667-Supplementary-Table-S2.pdf
Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures.
Guerin N et al.
Cell Systems, 2022
BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS.
Röck R et al.
Science Advances, 2019
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
Henry JR et al.
Journal of Medicinal Chemistry, 2015
Gatekeeper mutations mediate resistance to BRAF-targeted therapies.
Whittaker S et al.
Science Translational Medicine, 2010
Select a paper to view details